Similarly, given the relevance of inflammatory mediators, and particularly IL-1β, in the pathophysiology of diabetes and diabetic cardiomyopathy [127], targeting the NLRP3/IL1β pathway could effectively reduce the burden of this disease. The gene discussed is IL1B; the disease is diabetic cardiomyopathy.